SMALL_CELL_LUNG_CANCER US . HENGENIX BIOTECH, Una Filial de SHANGHÁI HENLIUS BIOTECH , Utilizará la Plataforma PROPHET de ONCOHOST Para Identificar BIOMARCADORES en un Ensayo de Fase III Que Prueba el Anticuerpo Anti-PD-1 de Henlius, SERPLULIMAB Más QUIMIOTERAPIA en Pacientes con Cáncer de Pulmón de Células Pequeñas en Estadio Extenso .

  

SERPLULIMAB ESTA EN ENSAYOS CLÍNICOS DE FASE III EN INTENTO DE PODER SER UNO DE LOS TRATAMIENTOS STANDARD DE PRIMERA LINEA PARA SMALL-CELL LUNG CÁNCER A NIVEL MUNDIAL Y DESBANCAR A LOS TRATAMIENTOS ACTUALES  .

OncoHost, Hengenix Biotech Exploring Lung Cancer Resistance Biomarkers in Immunotherapy Trial .

Oct 03, 2023 | staff reporter .

NEW YORK – Hengenix Biotech, an affiliate of Shanghai Henlius Biotech, will use OncoHost's Prophet platform to identify Biomarkers in a Phase III trial testing Henlius' anti-PD-1 Antibody SERPLULIMAB plus CHEMOTHERAPY in Patients with EXTENSIVE-STAGE SMALL CELL LUNG CÁNCER (ES-SCLC) .

OncoHost on Tuesday said that in the Phase III Trial researchers will compare the activity of SERPLULIMAB plus CHEMOTHERAPY against Roche's anti-PD-1 Antibody TECENTRIQ (atezolizumab) plus CHEMOTHERAPY in previously untreated ES-SCLC patients . They will use the Prophet platform to look for proteomic biomarkers that characterize resistance patterns in patients with the goal of identifying those most likely to benefit from the SERPLULIMAB - Chemotherapy Combination . ...